Cotellic (cobimetinib) is an oral kinase inhibitor primarily utilized in oncology. It works by inhibiting MEK1 and MEK2, key enzymes in the MAPK/ERK signaling pathway, which plays a crucial role in cell division and survival. By blocking this pathway, Cotellic helps slow down the growth of cancer cells.

This drug is approved for the treatment of adult patients with unresectable or metastatic melanoma with a BRAF V600E or V600K mutation, in combination with vemurafenib. Additionally, it is approved for the treatment of adult patients with histiocytic neoplasms as a monotherapy. It is essential for clinicians to confirm the presence of the BRAF V600E or V600K mutation before initiating Cotellic in melanoma patients.